pyrroles has been researched along with Thyroid Cancer, Anaplastic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alì, G; Antonelli, A; Basolo, F; Bocci, G; Di Desidero, T; Ferrari, SM; Fioravanti, A; Fontanini, G; Francia, G; Orlandi, P | 1 |
| Cheng, SY; Lee, WK; Park, S; Zhu, X | 1 |
| Champa, D; Cuervo, AM; Di Cristofano, A; Orlacchio, A; Patel, B; Ranieri, M; Shemetov, AA; Verkhusha, VV | 1 |
| Chen, S; Wang, W; Zhao, L; Zhou, J | 1 |
| Asselineau, J; Bournaud-Salinas, C; Caron, P; Catargi, B; Daste, A; de la Fouchardière, C; Delord, JP; Digue, L; Do Cao, C; Doussau, A; Gimbert, A; Klein, M; Nicolli-Sire, P; Pedenon, D; Picat, MQ; Pouessel, D; Ravaud, A; Rodien, P; Wemeau, JL | 1 |
| Chan, AW; Odejide, OO; Schoenfeld, JD; Wirth, LJ | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ | 1 |
1 trial(s) available for pyrroles and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Pyrroles; Sunitinib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome | 2017 |
6 other study(ies) available for pyrroles and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Synergism; Female; Humans; Indoles; Irinotecan; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Thyroid Carcinoma, Anaplastic | 2017 |
Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Proliferation; Diphenylamine; Drug Synergism; Female; Humans; MAP Kinase Kinase 1; Mice; Mice, Nude; Oxazoles; Pyridines; Pyrroles; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Cell Proliferation; Enzyme Inhibitors; Humans; Indoles; Lysosomes; Mefloquine; Mice; Mice, Knockout; Necrosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA Interference; RNA, Small Interfering; Spheroids, Cellular; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Tumor Cells, Cultured | 2016 |
Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Topics: Aminoacetonitrile; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Humans; Indoles; Mice, Nude; Pyrroles; Sunitinib; Taxoids; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2017 |
Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Chemoradiotherapy; Female; Humans; Indoles; Middle Aged; Pyrroles; Radiotherapy, Intensity-Modulated; Sunitinib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2012 |
CCAAT/Enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.
Topics: Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Drug Screening Assays, Antitumor; Gene Knockdown Techniques; Humans; Indoles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Transcription Factor CHOP; Tumor Suppressor Protein p53 | 2013 |